Lupus Research Alliance and Lupus Therapeutics Response to Positive Data from Phase 2 Study on Potential First-in-class Lupus Treatment

The Lupus Research Alliance and its clinical trial arm Lupus Therapeutics respond to Bristol Myers Squibb’s new positive results from a Phase II trial of its investigational agent deucravacitinib for the treatment of systemic lupus erythematosus